Abcellera Biologics Inc (ABCL) stock forecast · rev $12.4M
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
This ABCL forecast page states what the cached financials imply — not a price target and not a guarantee. Abcellera Biologics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
The near-term path: Revenue was up 48.7% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
ABCL currently screens at market cap $1.12B. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ABCL 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ABCL stock page.
Not investment advice.